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Edited by Masayuki MiyasakaAbstract By varying linker length and domain orientation three
multivalent derivatives of a monovalent anti-CD22 single-chain
fragment variable (scFv) antibody were generated. Shortening
the linker of the VH–VL oriented scFv to 5 or 0 residues resulted
in the formation of diabodies or a mixture of tetramers and tri-
mers, respectively. Unexpectedly, a VL–0–VH scFv assembled to
homogenous dimers, remained substantially more stable than the
VH–5–VL diabody when incubated in human serum at 37 C, and
retained its dimeric state when concentrated up to 4 mg/ml.
These properties suggest the VL–0–VH scFv could become an
attractive vehicle for the selective delivery of multiple eﬀector
molecules to CD22+ tumor cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Single-chain fragment variable (scFv) antibodies have be-
come a popular format of engineered antibodies. They have
gained substantial clinical interest by their use as vehicles to de-
liver diagnostic and therapeutic agents such as radionuclides,
enzymes, or toxins, selectively to tumor target cells [1–3].
Although monovalent scFvs can penetrate solid tumor tissue
more eﬃciently than whole antibodies [4] they are cleared from
the circulation within minutes after administration and areAbbreviations: scFv, single-chain Fv antibody; Fv, fragment variable;
VH, variable region from antibody heavy chain; VL, variable region
from antibody light chain; mAb, monoclonal antibody; SDS, sodium
dodecyl sulphate; PAGE, polyacrylamide gel electrophoresis; KD, bi-
nding aﬃnity equilibrium constant; IMAC, immobilized metal aﬃnity
chromatography
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doi:10.1016/j.febslet.2004.11.011poorly retained at tumor sites [4–7]. These properties particu-
larly limit therapeutic applications of such reagents.
To increase the size and apparent binding aﬃnity of mono-
valent scFvs, they can easily be engineered into oligomeric spe-
cies through manipulation of the linker peptide connecting the
variable domains. Holliger and colleagues pioneered the con-
struction of a bivalent molecule by shortening the linker pep-
tide to ﬁve residues, which prevents pairing of the variable
domains on the same polypeptide chain but promotes associa-
tion of two molecules to a bivalent diabody [8]. Further short-
ening the linker peptide below three residues was shown to
result in the formation of trimeric, tetrameric, or larger aggre-
gate species [9–12]. More recently, the formation of VH–VL
oriented scFv antibodies with <3 residue linkers to predomi-
nantly dimeric molecules has been described [13,14]. Several
studies have shown that in comparison with monovalent coun-
terparts, multivalent scFv fragments exhibited increased func-
tional antigen binding aﬃnity [12,15], favorable in vivo
retention within tumor tissue [7,16,17], and markedly slower
clearance from the bloodstream [6,18]. These properties sug-
gest multivalent scFv fragments to be excellent candidates
for the fusion with small antineoplastic eﬀector molecules.
The success of scFv antibodies in clinical applications fur-
ther relies on suﬃcient thermal stability, because it was shown
that only stable scFv molecules enriched at xenografted tumors
in severe combined immunodeﬁciency mice [19]. We recently
described the generation of the highly stable scFv fragment
MJ-7 (VH–15–VL) [20] that derived from the clinically estab-
lished, internalizing anti-CD22 monoclonal antibody (mAb)
LL2 [21]. This construct, obtained after rational mutagenesis
of three destabilizing residues within the variable region from
antibody heavy chain (VH) domain core structure, retained
similar antigen binding properties as the wild-type scFv but
exhibited several orders of magnitude greater stability when
incubated in human serum at 37 C.
To exploit the described advantages of using multimeric
scFvs as therapeutic targeting molecules, we aimed this study
at the construction of stable multimeric derivatives of the
monovalent anti-CD22 scFv MJ-7.2. Material and methods
2.1. Construction of multivalent anti-CD22 antibodies
The cDNA encoding the previously constructed anti-CD22 scFv
MJ-7 [20] was used to generate scFv multimers. A bivalent diabody
(MLD-6) was constructed by shortening the 15 amino acid linker
between the VH and variable region from antibody light chain (VL)ublished by Elsevier B.V. All rights reserved.
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MLT-1 with the VH domain directly linked to the VL domain, the
VH domain of scFv MJ-7 was PCR ampliﬁed with ﬂanking restriction
sites NcoI and EcoRV. The NcoI/EcoRV digested PCR fragment was
ligated into cleaved bacterial expression plasmid pHOG21/MJ-7 [20].
For cloning of scFv MLT-7 with variable domains directly joined in
the opposite orientation (VL–0–VH), the variable domain encoding
genes were PCR ampliﬁed in separate reactions and assembled by
overlap extension PCR as described in [22]. The resulting PCR frag-
ment was cloned into the NcoI/BamHI restricted plasmid pHOG21/
MJ-7. Correct sequences of scFv encoding fragments were veriﬁed
by automated DNA sequencing.Fig. 1. Schematic illustration of anti-CD22 scFv constructs. (a) ScFv
expression cassette with locations of lac promoter/operator (P/O); pelB
leader sequence (pelB); c-myc tag (c-myc) and hexahistidine tag (His6).
(b) Variable domain orientation (VH, VL) with linker peptide and
amino acid sequences of variable domain junction for each construct.2.2. Expression and puriﬁcation of scFv multimers
ScFv fragments were expressed using the E. coli strain TG1
(Stratagene, La Jolla, CA), isolated from the periplasm and puriﬁed
by immobilized metal aﬃnity chromatography (IMAC) as previously
described [20]. Aﬃnity puriﬁed scFv fragments were fractionated by
size-exclusion chromatography using either a calibrated Superdex 75
HR 10/30 column (Amersham Pharmacia, Piscataway, NJ) or a
Superdex 200 HR 10/30 column (Amersham Pharmacia) in phos-
phate buﬀered saline and 50 mM imidazole, pH 7.4, with a ﬂow rate
of 0.3 ml/min. The purity of size-fractionated antibodies was moni-
tored by sodium dodecyl sulphate–polyacrylamide gel electrophoresis
(SDS–PAGE) under reducing conditions after staining with Simply
Blue Safe Stain (Invitrogen, Carlsbad, CA). The speciﬁcity of
eluted fractions was determined by Western blot analysis using an
anti-(c-myc)-peroxidase conjugated mAb (Roche, Indianapolis, IN)
followed by chemiluminiscent detection (ECL Plus, Amersham
Pharmacia).Fig. 2. SDS gel electrophoresis of aﬃnity-puriﬁed scFv fragments
under reducing conditions. Lanes: M, molecular weight markers; 1,
MJ-7 (VH–15–VL); 2, MLD-6 (VH–5–VL); 3, MLT-7 (VL–0–VH) and 4,
MLT-1 (VH–0–VL). The gel was stained with Simply Blue
 Safe Stain.2.3. Cell binding measurements
Speciﬁc binding of the constructs was determined by ﬂow cytometry
using the human CD22+ B cell lines Raji and Daudi (American Type
Culture Collection, Manassas, VA) and the CD22 T cell lines Jurkat
and HUT102 (American Type Culture Collection) as control. Staining
was performed as previously described [20]. Stained cells were analyzed
on a FACScan Flow Cytometer (BD Bioscience, San Jose, CA) and the
median ﬂuorescence intensity (MFI) was calculated using the Cell-
Quest software (BD Bioscience). Binding aﬃnity constants (KD) were
measured as previously described [20,23].2.4. Biophysical stability analysis
At a concentration of 20 lg/ml, scFv fragments were incubated in
90% human serum at 37 C for up to 7 days. Samples were taken at
diﬀerent time points and frozen at 20 C until the end of the exper-
iment. Samples were subsequently analyzed for binding activity to
CD22+ Raji cells by ﬂow cytometry.3. Results
3.1. Construction of scFv multimers
To create multivalent scFv molecules, three scFv constructs
diﬀering in linker length and orientation of the variable do-
mains were made. The stable LL2-derived scFv MJ-7 [20], in
which the VH domain is separated from the VL domain by a
15 amino acid residue linker, was used as a template (Fig. 1).
In order to produce a bivalent diabody [8], the VH–VL orienta-
tion of the parental scFv MJ-7 was preserved and the linker
shortened to ﬁve amino acids (MLD6, Fig. 1). To direct scFv
association into multimers with more than two binding sites
[9–11,24], the variable domains of scFv MJ-7 were directly
connected to each other both in VH–0–VL (scFv MLT-1)
and reversed orientation (scFv MLT-7) (Fig. 1). ScFv genes
were fused at their C-terminal ends with a c-myc and a hexah-
istidine epitope tag for detection and puriﬁcation purposes,
respectively.3.2. Expression, puriﬁcation and biophysical analyses
All antibody fragments were produced as soluble proteins in
E. coli and puriﬁed from the bacterial periplasm by IMAC.
Aﬃnity puriﬁed scFv fragments migrated as single bands with
an expected molecular mass (27–30 kDa) on a reducing SDS–
PAGE gel (Fig. 2).
To examine the multimerization behavior of the scFv frag-
ments, size exclusion chromatography was performed. ScFvs
MJ-7 and MLD-6, containing either 15 or 5 amino acid link-
ers, respectively, were analyzed on a calibrated Superdex 75
column (Fig. 3(a)). ScFv MJ-7 eluted in two peaks (12.5 ml
and 10.9 ml) corresponding to monomers (29 kDa; 63%) and
dimers (54 kDa; 37%), respectively (Fig. 3(a), Table 1).
MLD-6 showed a predominant peak at an elution volume of
11 ml corresponding to a diabody (96%) and an additional
small peak indicating tetramers (Fig. 3(a), Table 1). Gel ﬁltra-
tion on a calibrated Superdex 200 column of the fragments
with directly linked variable domains revealed for the VH–0–
VL construct MLT-1 a heterogeneous mixture of molecules
with apparent molecular masses corresponding to trimers (84
kDa; 39%) and tetramers (112 kDa; 61%) (Fig. 3(b), Table
1). MLT-7 (VL–0–VH) showed an unexpected elution proﬁle
with a major peak (95%) eluting at 15.4 ml corresponding to
an apparent molecular mass of a dimeric scFv fragment and
only a small proportion (5%) of tetramers eluting at 13.7 ml
(Fig. 3(b), Table 1). MLT-1 formed a non-separable equilib-
rium between trimers and tetramers and was therefore ex-
cluded from further investigation.
Fig. 4. Equilibrium binding curves of anti-CD22 antibody fragments.
Binding activity to CD22+ Raji cells of scFv monomer MJ-7 and
dimeric scFvs MLD-6 and MLT-7 was determined by ﬂow cytometry
and is shown as median ﬂuorescence intensity (MFI) with subtracted
background ﬂuorescence. Bars represent standard deviation.
Fig. 5. Size exclusion chromatography of dimeric scFv fragments on a
calibrated Superdex 75 column. Superimposed are elution proﬁles of
concentrated MLT-7 (4 mg/ml; solid line) and MLD-6 (2.8 mg/ml:
dotted line). (D) dimers, (T) tetramers.
Fig. 6. Serum stability of scFv dimers. Immunoreactivity of dimeric
scFv fragments MLD-6 and MLT-7 with CD22+ Raji cells was
determined after incubation in human serum at 37 C at indicated time
points.
Fig. 3. Size-exclusion chromatography of aﬃnity puriﬁed anti-CD22
scFvs. Superimposed are elution proﬁles from a (a) Superdex 75 gel
ﬁltration column of scFv MJ-7 (solid line) and diabody MLD-6
(dashed line) and (b) Superdex 200 gel ﬁltration column of zero-linker
constructs MLT-1 (solid line) and MLT-7 (dashed line). Elution peaks
and molecular weight of calibration reference proteins are indicated.
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Flow cytometry analysis revealed speciﬁc binding of all scFv
fragments to the CD22+ cell lines Raji and Daudi and no bind-
ing to the CD22 cell lines Jurkat and HUT102 (data not
shown). Aﬃnity constants of the antibody fragments for bind-
ing to CD22+ Raji cells were determined by ﬂow cytometry.
All three scFv fragments showed an antibody concentration-
dependent increase in ﬂuorescence intensity (Fig. 4). Fitting
the data from the equilibrium-binding curves into the non-lin-
ear regression model according to the Levenberg–Marquard
method revealed a 3.5-fold higher apparent aﬃnity for the dia-body MLD-6 than the parental scFv MJ-7 (Table 1). Diabody
MLD-6 retained the same apparent aﬃnity as the murine mAb
LL2 [20] (KD 4.8 nM vs. 4.7 nM). In contrast, the zero-linker
dimer MLT-7 bound CD22+ Raji cells with an apparent aﬃn-
ity similar to that of the monovalent scFv MJ-7 (Table 1).3.4. Stability of dimeric scFvs
The oligomeric status of scFvs can strongly be inﬂuenced by
the protein concentration. Therefore, following IMAC puriﬁ-
cation and gel ﬁltration, dimeric MLD-6 and MLT-7 were
concentrated to >1 mg/ml and further characterized by size
exclusion chromatography using a calibrated Superdex 75 col-
umn. About 18% of the puriﬁed diabody MLD-6 converted to
tetramers when concentrated to 2.8 mg/ml (Fig. 5). In contrast,
a deﬁned dimeric status was kept for MLT-7 at protein con-
centrations >1 mg/ml and only at the highest tested protein
concentration of 4 mg/ml a small fraction of tetramers
(4%) was observed (Fig. 5).
The thermostability of the dimeric molecules MLD-6 and
MLT-7 was analyzed. Diabody MLD-6 (VH–G4S–VL) lost
50% of its initial binding activity after only 12 h incubation
in human serum at 37 C and completely lost binding activity
after 48 h incubation time (Fig. 6, Table 1). In contrast, the di-
meric molecule MLT-7 (VL–0–VH) remained fully active after
a 12 h incubation period, exhibited an 8-fold greater half life
Table 1
Variant Format (%)a KD (nM)
b t1/2 (h)
c
Monomer Dimer Trimer Tetramer
MJ7 63 37 16.6 >144
MLD6 96 4 4.8 12
MLT1 39 61 n.d. n.d.
MLT7 95 5 18.7 96
aDeduced from size exclusion chromatography.
bEquilibrium constants (KD) deduced from binding to tumor cells measured by ﬂuorescence cytometry.
cDetermined from binding activity to tumor cells after incubation in human serum at 37 C.
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days (Fig. 6, Table 1).4. Discussion
The purpose of this study was to generate and characterize
multivalent scFv antibody derivatives from a stable anti-
CD22 scFv fragment, previously obtained by rational muta-
genesis of three destabilizing VH common core residues [20].
The most straightforward method to generate a multivalent
scFv is to shorten the variable domain connecting linker pep-
tide, thereby allowing for the non-covalent association of
multiple polypeptide chains to a dimeric or multimeric mole-
cule [8–12,24,25]. In addition to the linker length, the orien-
tation of the variable domains was shown to impact the
multimerization behavior of the polypeptide chains [9,10],
an eﬀect largely attributed by the asymmetry of variable light
chain and heavy chain domains [26,27]. We therefore made
several scFv variants diﬀering in both linker length and do-
main orientation. Consistent with reports of other scFvs gen-
erated in the same domain orientation and with the same 15
amino acid linker, the monovalent scFv MJ-7 exhibited an
inherent tendency to form dimers [8,10]. Likewise, shortening
the linker of the scFv MJ-7 in this orientation to ﬁve residues
(Gly4Ser) resulted in the almost exclusive formation of biva-
lent diabodies [8,10]. The deduced functional aﬃnity of the
MLD-6 diabody was similar to that determined for the par-
ent mAb LL2, reﬂecting the gain in avidity due to dimeriza-
tion and capability of the molecule for simultaneous binding
to two epitopes.
It has been described that further shortening the linker to
less than three residues promotes the formation of molecules
with three or four antigen binding sites, ‘‘triabodies’’ or ‘‘tet-
rabodies’’, respectively [28]. Linker dependent oligomeriza-
tion behavior of the murine anti-neuraminidase scFv NC10
[29] has been studied in detail. Joining VHS112 to VLD1 of
scFv NC10 by 3–0 residues resulted in a precise transition
from dimers into trimers [25]. Another study examining the
linker-length dependent oligomerization behavior of the
HD37 derived anti-CD19 scFv in VH–VL orientation reported
an exclusive trimer formation by fusing VHS112 to VLD1 and
an unexpected exclusive tetramer conformation when VHS113
was ligated to VLD1 [12]. When joining VHS113 to VLD1 of
an OKT-3 derived scFv, however, formation of 40% dimers
and 60% trimers was observed [14]. In the present study we
observed an equilibrium between trimers and tetramers when
joining VHS113 to VLD1 (scFv MLT-1), indicating that lin-ker dependent oligomerization behavior of scFv fragments
may also be dictated by the particular antibody VH/VL
sequence.
Because the distance between the carboxyl terminus end of
VL and the amino terminus of VH is greater than that for
the opposite orientation, it has been discussed that VL–VH ori-
entated scFvs are more constrained than VH–VL oriented frag-
ments when connected by the same linker and therefore tend to
exhibit a higher tendency to form higher molecular weight olig-
omers [30]. Experimental evidence for this assumption has
been presented for scFv NC10 by demonstrating that direct
linkage of the variable domains in VL–VH orientation resulted
in the predominant formation of tetrabodies [9], whereas in re-
versed orientation formation of trimers was described [10].
Thus, the association of scFv MLT-7 (VL–0–VH) to homoge-
neous dimers in the present study was unexpected. To our
knowledge, the exclusive formation of a zero linker scFv con-
struct in VL–0–VH orientation to a dimer has not yet been de-
scribed, further conﬁrming the notion that linker length
dependent scFv multimerization may substantially vary among
diﬀerent antibodies and thus cannot reliably be predicted.
Despite its bivalency, and in contrast to the VH–5–VL
oriented diabody MLD-6, the VL–0–VH dimer MLT-7
bound to the target antigen with a similar apparent aﬃn-
ity as the monovalent counterpart MJ-7. Possible explana-
tions for this phenomenon could be incorrect association
of one pair of the VL/VH domains, inability of the di-
meric molecule to span the distance for simultaneously
binding to two epitopes, or binding of both antigen bind-
ing sites but each with reduced intrinsic aﬃnity due to
steric constraints of the molecule.
Despite its weaker binding aﬃnity, the VL–0–VH dimer
MLT-7 exhibited a markedly superior thermostability over
the VH–5–VL oriented diabody MLD-6 and showed no ten-
dency to form higher molecular weight species even at concen-
trations of up to 4 mg/ml. For clinical applications, this is a
most important property because even highly robust monova-
lent scFvs were shown to multimerize especially at concentra-
tions >1 mg/ml [31]. The formation of stable dimers may
indicate that the VL–0–VH MLT-7 interface may structurally
be less constrained than that of the VH–5–VL diabody MLD-
6. To elucidate the structural basis for this phenomenon on a
molecular level, the scFv fragment will be crystallized within
the near future.
In conclusion, we have generated a scFv without a linker in
VL–0–VH orientation that associates to a highly stable dimeric
molecule. We expect that this antibody may become an attrac-
tive targeting moiety for the subsequent generation of novel
M.A.E. Arndt et al. / FEBS Letters 578 (2004) 257–261 261immunotherapeutic reagents for CD22+ B-cell Non-Hodgkins
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